This is a revised competing renewal application for K24 funding. The candidate is a pediatric hematologist and geneticist, with basic science training in biochemistry and molecular biology, and a clinical research background in pediatric blood, lipid and vascular disorders. The primary goal for this award is to provide protected time for mentoring in the setting of several ongoing patient-oriented research projects in pediatric blood disorders. In the long run, the goal is to establish the PI as a senior mentor for students, residents, fellows, and junior members interested in patient-oriented research in pediatric hematology and genetics. The study environment is the Pediatric Hematology/Oncology program of Children's Hospital Boston and Dana Farber Cancer Institute. Opportunities for mentoring include Harvard undergraduates, local and visiting medical students, residents and fellows not limited to those in hematology, and junior faculty members launching careers in academic medicine and patient oriented research. In this revised application, the focus is on """"""""bedside to bench"""""""" analysis of the genetic pathophysiology of blood disorders, divided into two projects.
The first aim /project is to further characterize the rare human disorder, thiamine-responsive megaloblastic anemia, due to defects in the gene for high-affinity thiamine transporter, SLC19A2. In the first K24 support period, the candidate's lab identified the causative gene and many patients'mutations. Further studies of mutations of this SLC19A2 gene will be performed on recently identified patients with TRMA, and related disorders. [3H]Thiamine uptake studies and stable isotope metabolic profiling with [1,2-13C]glucose, both methods developed in the initial grant period, will be pursued for cells from patients with interesting TRMA variants, including one with no detectable SLC19A2 mutation. A murine model of TRMA, developed in the first K24 period for pathophysiology studies not possible in humans, will be utilized for marrow studies that will further elucidate the pathophysiology of the disorder. Marrow transplantation from TRMA mice into normal will determine if the marrow defect is cell-intrinsic. In the second aim, candidate gene sequencing will be used to identify the cause of rare inherited blood diseases identified in the hematology program at Children's Hospital. Using this approach, several unique disorders of blood clotting and anemia have been studied.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24HL004184-09
Application #
7642327
Study Section
Special Emphasis Panel (ZHL1-CSR-R (M1))
Program Officer
Werner, Ellen
Project Start
1999-08-15
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
9
Fiscal Year
2009
Total Cost
$177,732
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Obeng, Esther A; Harney, Kathy M; Moniz, Thomas et al. (2015) Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr 166:144-50
Morrison, Jacqueline F; Neufeld, Ellis J; Grace, Rachael F (2014) The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. Eur J Haematol 93:161-4
Grace, Rachael F; Long, Michelle; Kalish, Leslie A et al. (2012) Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatr Blood Cancer 58:216-20
Grace, Rachael F; Bennett, Carolyn M; Ritchey, A Kim et al. (2012) Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer 58:221-5
Long, Michelle; Kalish, Leslie A; Neufeld, Ellis J et al. (2012) Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects. Am J Hematol 87:315-7
Sobota, Amy; Graham, Dionne A; Neufeld, Ellis J et al. (2012) Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer 58:61-5
Grace, Rachael F; Dahlberg, Suzanne E; Neuberg, Donna et al. (2011) The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152:452-9
Trenor 3rd, Cameron C; Chung, Richard J; Michelson, Alan D et al. (2011) Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 127:347-57
Sobota, Amy; Neufeld, Ellis J; Sprinz, Philippa et al. (2011) Transition from pediatric to adult care for sickle cell disease: results of a survey of pediatric providers. Am J Hematol 86:512-5
Oyeku, Suzette O; Feldman, Henry A; Ryan, Kathleen et al. (2010) Primary care clinicians' knowledge and confidence about newborn screening for sickle cell disease: randomized assessment of educational strategies. J Natl Med Assoc 102:676-82

Showing the most recent 10 out of 44 publications